JP2014520784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520784A5 JP2014520784A5 JP2014517813A JP2014517813A JP2014520784A5 JP 2014520784 A5 JP2014520784 A5 JP 2014520784A5 JP 2014517813 A JP2014517813 A JP 2014517813A JP 2014517813 A JP2014517813 A JP 2014517813A JP 2014520784 A5 JP2014520784 A5 JP 2014520784A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- region
- antibody specific
- composition
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161504744P | 2011-07-06 | 2011-07-06 | |
| EP11172865 | 2011-07-06 | ||
| US61/504,744 | 2011-07-06 | ||
| EP11172865.5 | 2011-07-06 | ||
| PCT/EP2012/063207 WO2013004806A1 (en) | 2011-07-06 | 2012-07-06 | Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014520784A JP2014520784A (ja) | 2014-08-25 |
| JP2014520784A5 true JP2014520784A5 (https=) | 2015-08-13 |
Family
ID=47436548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517813A Pending JP2014520784A (ja) | 2011-07-06 | 2012-07-06 | 抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140234298A1 (https=) |
| EP (1) | EP2729498A1 (https=) |
| JP (1) | JP2014520784A (https=) |
| KR (1) | KR20140061379A (https=) |
| CN (1) | CN103827143A (https=) |
| AU (2) | AU2012280267B2 (https=) |
| BR (1) | BR112013033944A2 (https=) |
| CA (1) | CA2839513A1 (https=) |
| RU (1) | RU2013156435A (https=) |
| WO (1) | WO2013004806A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37946B1 (fr) | 2012-09-20 | 2018-09-28 | Morphosys Ag | Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde |
| WO2016079276A1 (en) * | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease |
| EP3108897A1 (en) * | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| KR20180012873A (ko) * | 2015-06-24 | 2018-02-06 | 에프. 호프만-라 로슈 아게 | 림프종 또는 백혈병에서 림프구증가증의 유도에 사용하기 위한 인간 csf-1r에 대한 항체 |
| GB201519331D0 (en) * | 2015-11-02 | 2015-12-16 | Glaxosmithkline Ip Dev Ltd | Treatment paradigm |
| WO2018045117A1 (en) * | 2016-09-01 | 2018-03-08 | The Regents Of The University Of Colorado, A Body Corporate | Methods of treating eosinophilic gastrointestinal diseases |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| AU2018345751A1 (en) | 2017-10-02 | 2020-05-07 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| US11655293B2 (en) | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| JP7603580B2 (ja) | 2018-10-15 | 2024-12-20 | エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド | 顆粒球マクロファージコロニー刺激因子に対する抗体及びそれらの使用 |
| WO2020092850A1 (en) * | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
| AU2019377515A1 (en) * | 2018-11-09 | 2021-05-27 | Kiniksa Pharmaceuticals, Gmbh | Treatment for giant cell arteritis |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CA3137908A1 (en) * | 2019-04-25 | 2020-10-29 | Actinium Pharmaceuticals, Inc. | Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2022093855A1 (en) * | 2020-10-26 | 2022-05-05 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cancers with gm-csf antagonists |
| EP4328243A4 (en) * | 2021-04-20 | 2025-05-21 | Korea University Research and Business Foundation | Asymmetric antibody with improved cytotoxicity against cancer cell |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DK0752248T3 (da) * | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| ES2543819T3 (es) | 1998-11-09 | 2015-08-24 | Biogen Inc. | Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20 |
| EP1156823B1 (en) | 1999-02-12 | 2008-10-29 | The Scripps Research Institute | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| JP2006500905A (ja) | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| WO2003068821A2 (en) | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| BRPI0608281B8 (pt) | 2005-04-18 | 2021-05-25 | Amgen Res Munich Gmbh | anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende |
| RU2447085C2 (ru) * | 2005-05-18 | 2012-04-10 | МорфоСис АГ | Анти-gm-csf антитела и их применение |
| ZA200709956B (en) * | 2005-05-20 | 2009-02-25 | Genentech Inc | Pretreatment of a biological sample from an autoimmune disease subject |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| WO2007064911A1 (en) * | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| US7741450B2 (en) * | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
| EP2101780B1 (en) * | 2006-11-21 | 2013-10-09 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| CN101687926A (zh) | 2007-05-23 | 2010-03-31 | 哮喘和气道Crc有限公司 | 中和抗体 |
| CA2690858A1 (en) * | 2007-06-07 | 2008-12-18 | Surmodics Pharmaceuticals, Inc. | Reduced-mass, long-acting dosage forms |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| WO2009062238A1 (en) | 2007-11-12 | 2009-05-22 | Crc For Asthma And Airways Ltd | Epitope for neutralizing antibodies |
| CN104072613A (zh) | 2007-11-13 | 2014-10-01 | Evec股份有限公司 | 与hGM-CSF结合的单克隆抗体及包含它的药物组合物 |
| WO2009134805A2 (en) | 2008-04-28 | 2009-11-05 | Kalobios Pharmaceuticals, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
| CA2717987C (en) | 2008-04-29 | 2018-11-13 | Micromet Ag | Inhibitors of gm-csf and il-17 for therapy |
| US20100122819A1 (en) | 2008-11-17 | 2010-05-20 | Baker Hughes Incorporated | Inserts with Swellable Elastomer Seals for Side Pocket Mandrels |
| KR20110128876A (ko) * | 2009-02-16 | 2011-11-30 | 바이오렉스 쎄라퓨틱스, 인코포레이티드 | 인간화된 항-ｃｄ20 항체 및 이용 방법 |
| US20100247484A1 (en) | 2009-03-31 | 2010-09-30 | Heinrich Barchet | Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3 |
| US8609101B2 (en) | 2009-04-23 | 2013-12-17 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies |
-
2012
- 2012-07-06 CN CN201280033421.3A patent/CN103827143A/zh active Pending
- 2012-07-06 WO PCT/EP2012/063207 patent/WO2013004806A1/en not_active Ceased
- 2012-07-06 RU RU2013156435/10A patent/RU2013156435A/ru not_active Application Discontinuation
- 2012-07-06 AU AU2012280267A patent/AU2012280267B2/en not_active Ceased
- 2012-07-06 JP JP2014517813A patent/JP2014520784A/ja active Pending
- 2012-07-06 CA CA2839513A patent/CA2839513A1/en not_active Abandoned
- 2012-07-06 KR KR1020147003186A patent/KR20140061379A/ko not_active Withdrawn
- 2012-07-06 EP EP12735498.3A patent/EP2729498A1/en not_active Withdrawn
- 2012-07-06 BR BR112013033944A patent/BR112013033944A2/pt not_active IP Right Cessation
- 2012-07-06 US US14/130,667 patent/US20140234298A1/en not_active Abandoned
-
2016
- 2016-03-18 AU AU2016201736A patent/AU2016201736A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520784A5 (https=) | ||
| RU2013156435A (ru) | Терапевтические комбинации анти-cd20 и анти-gm-csf антител и их применения | |
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| SG10201903475TA (en) | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
| NZ607394A (en) | Vegf-binding molecules | |
| NZ728636A (en) | Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor | |
| JP2018521691A5 (https=) | ||
| JP2015530399A5 (https=) | ||
| HK1203372A1 (en) | Chimeric therapeutic anti - cd37 antibodie hh1 | |
| WO2017184619A3 (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
| HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
| NZ714079A (en) | Purification process for monoclonal antibodies | |
| UA118255C2 (uk) | Композиція, яка містить антитіло до cd38 і леналідомід | |
| JP2016520514A5 (https=) | ||
| NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
| NZ710695A (en) | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof | |
| MX2013009774A (es) | Anticuerpo de fc especifico para fcyriib. | |
| JP2014176384A5 (https=) | ||
| WO2012149356A3 (en) | Anti-cd40 antibodies and methods of use | |
| UA115781C2 (uk) | Cx3cr1-зв'язуючий поліпептид | |
| WO2015023504A8 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| WO2016063026A3 (en) | Selective nav protein binders | |
| WO2016022589A3 (en) | Methods for treating multiple myeloma | |
| JP2019529514A5 (https=) | ||
| SG10201803778PA (en) | Treatment for rheumatoid arthritis |